Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09MHC
|
|||
| Former ID |
DNCL002841
|
|||
| Drug Name |
CJC-1134-PC
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 3 | [1], [2], [3] | |
| Company |
ConjuChem
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C26H47N7O9S
|
|||
| Canonical SMILES |
C1C(C(=O)N(C1=O)CCC(=O)NCCOCCOCC(=O)NCCCCNCCCCC(C(=O)N)N)SCC(C(=O)O)N
|
|||
| InChI |
1S/C26H47N7O9S/c27-18(24(29)37)5-1-2-7-30-8-3-4-9-31-22(35)16-42-14-13-41-12-10-32-21(34)6-11-33-23(36)15-20(25(33)38)43-17-19(28)26(39)40/h18-20,30H,1-17,27-28H2,(H2,29,37)(H,31,35)(H,32,34)(H,39,40)/t18-,19-,20?/m0/s1
|
|||
| InChIKey |
MSFZPBXAGPYVFD-NFBCFJMWSA-N
|
|||
| CAS Number |
CAS 1031700-39-6
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). | |||
| REF 2 | Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77. | |||
| REF 3 | Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR). Rev Med Liege. 2014 Apr;69(4):214-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.